1. PI3K/Akt/mTOR
  2. PI3K


Cat. No.: HY-15837
Handling Instructions

SAR-260301 is a selective PI3Kβ inhibitor with an IC50 of 23 nM.

For research use only. We do not sell to patients.

SAR-260301 Chemical Structure

SAR-260301 Chemical Structure

CAS No. : 1260612-13-2

Size Price Stock
5 mg USD 130 Get quote
10 mg USD 230 Get quote
25 mg USD 490 Get quote
50 mg USD 880 Get quote
100 mg USD 1550 Get quote

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • References


SAR-260301 is a selective PI3Kβ inhibitor with an IC50 of 23 nM.

IC50 & Target[1]


23 nM (IC50)


468 nM (IC50)


1539 nM (IC50)


10000 nM (IC50)


183 nM (IC50)


3812 nM (IC50)


49 nM (IC50)


2000 nM (IC50)

In Vitro

In the UACC-62 tumor cell line assay, SAR-260301 inhibits pAktS473 with a measured IC50 at 0.06 μM and an estimated IC90 at 2 μM[1]. In MEF-3T3-myr-p110β mechanistic model, SAR260301 inhibits PI3Kβ-dependent proliferation/viability in low serum conditions with an IC50 of 196 nM. In PTEN-deficient human prostate tumor cells, SAR260301 inhibits LNCaP cell proliferation in low and high serum conditions with IC50 values of 2.9 and 5.0 μM, respectively, after 4-day treatment, whereas it is inactive in these conditions in PC3 cells at concentrations up to 10 μM, despite target engagement. After prolonged treatment, SAR260301 at 3 or 10 μM inhibits PC3 cell proliferation in low serum conditions, with a cytostatic effect achieved for 14 days, despite some cell death induction observed at 10 μM. SAR260301 also leads to antitumor activities in PTEN-deficient/BRAF-mutant human melanoma cells, inhibiting cell proliferation with IC40 values of 6.5 and 3.3 μM for UACC-62 and WM-266.4, respectively, after 4-day treatment[2].

In Vivo

SAR-260301 displays antitumor efficacy in human PTEN-deficient melanoma models in mice as a single agent. SAR-260301 treatment leads to a statistically significant tumor growth inhibition as measured by a ΔT/ΔC of 39% (p = 0.054 versus control mice) on day 15 post-tumor implantation. SAR-260301 is well tolerated at the active dose, with no sign of toxicity and no body weight loss. Oral administration of SAR-260301 reveals sustained target inhibition (≥50%) of pAkt-S473 for at least 7 h. SAR-260301 has moderate terminal elimination half-life (t1/2=0.87 h, 1.4 h, 2.5 h, 0.87h, 6.9 h and 4.5 h for female SCID mice (3 mg/kg, iv), mice (10 mg/kg, po), mice (100 mg/kg, po), female nude rats (3 mg/kg, iv), rat (10 mg/kg, po), male beagle dogs (10 mg/kg, po))[1].

Solvent & Solubility
In Vitro: 

10 mM in DMSO

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8217 mL 14.1084 mL 28.2167 mL
5 mM 0.5643 mL 2.8217 mL 5.6433 mL
10 mM 0.2822 mL 1.4108 mL 2.8217 mL
*Please refer to the solubility information to select the appropriate solvent.
Cell Assay

Cell proliferation is measured by quantifying intracellular ATP using CellTiter-Glo kit. Cells seeded into 96-well black microplates in complete medium, are treated with single or combined agents (e.g., SAR260301) 0.3 nM-30 μM (0.1% DMSO final concentration) for 96 hours. A matrix of concentrations is prepared to allow the interaction between two compounds at different proportions/ratios, each corresponding to a “ray”. The design includes one ray for each single agent (Rays 1 and 5) and 4 for combinations. The effective fractions, corresponding to the proportional effect of each compound alone according to their IC40 value, are estimated between 0.05 and 0.95. The combination rays correspond to SAR26030:Vemurafenib or SAR260301:Selumetinib ratio of 1:3, 1:1, 3:1 and 9:1, estimated based on effective fractions. These fractions are based on IC40 calculations because SAR260301 single agent being poorly active, IC40 values are better estimated than IC50[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

SAR-260301 is evaluated for its antitumor effects in UACC-62 melanoma subcutaneous xenografts in SCID mice. Tumors are allowed to reach at least 150 mm3 before treatment, and tumor volume is measured regularly over the treatment period. Mice are treated orally with SAR-260301 at the dose of 150 mg/kg using a bidaily (BID) schedule in order to favor sustained pathway inhibition and allow comparison with the study performed in PC3 model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight







O=C1N=C(CC(N2[[email protected]@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1


Please store the product under the recommended conditions in the Certificate of Analysis.


Room temperature in continental US; may vary elsewhere

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.:


Cat. No.: HY-15837